Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 33,617	$ 13,806
Accounts receivable, net of allowance for credit losses of $3,809 and $4,068 at 2021 and 2020, respectively	93,217	83,192
Inventories	38,946	38,151
Prepaid expenses	12,231	14,797
Income taxes receivable	16,951	9,675
Other current assets	6,187	6,227
TOTAL CURRENT ASSETS	201,149	165,848
PROPERTY, PLANT AND EQUIPMENT, net	112,398	115,293
RIGHT OF USE ASSETS	66,482	66,385
INTANGIBLES, net of accumulated amortization of $17,195 and $16,833 at 2021 and 2020, respectively	8,317	8,583
GOODWILL	99,445	99,445
DEFERRED TAX ASSETS, net	70,083	72,775
OTHER ASSETS	40,551	40,250
TOTAL ASSETS	598,425	568,579
CURRENT LIABILITIES:
Accounts payable	30,383	23,028
Accrued payroll and related costs	20,477	26,526
Taxes other than payroll and income	7,230	6,556
Unearned revenues	6,410	5,457
Operating lease liabilities	12,150	11,437
Income taxes payable	7,392	8,347
Other current liabilities	6,812	8,399
TOTAL CURRENT LIABILITIES	90,854	89,750
LONG-TERM DEBT, net	208,305	259,433
LONG-TERM OPERATING LEASE LIABILITIES	55,121	56,108
DEFERRED COMPENSATION	38,846	39,145
DEFERRED TAX LIABILITIES, net	20,677	20,585
OTHER LONG-TERM LIABILITIES	30,278	27,985
COMMITMENTS AND CONTINGENCIES
EQUITY:
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding	0	0
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 46,454,264 issued and 46,325,530 outstanding at 2021 and 44,796,252 issued and 44,572,801 outstanding at 2020	1,188	1,148
Additional paid-in capital	98,255	41,184
Retained earnings	65,712	50,456
Accumulated other comprehensive income (loss)	(10,138)	(7,200)
Treasury shares, at cost, 128,734 at 2021 and 223,451 at 2020	(4,992)	(14,075)
Total Core Laboratories N.V. shareholders' equity	150,025	71,513
Non-controlling interest	4,319	4,060
TOTAL EQUITY	154,344	75,573
TOTAL LIABILITIES AND EQUITY	$ 598,425	$ 568,579